SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-18-006504
Filing Date
2018-10-01
Accepted
2018-10-01 08:32:02
Documents
5
Period of Report
2018-10-31
Effectiveness Date
2018-10-01

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2236783zdef14a.htm DEF 14A 169745
2 G271152BGI001.GIF g271152bgi001.gif GRAPHIC 201301
3 G271152BGI002.GIF g271152bgi002.gif GRAPHIC 116133
4 G832816.JPG g832816.jpg GRAPHIC 21180
5 G761950.JPG g761950.jpg GRAPHIC 7584
  Complete submission text file 0001047469-18-006504.txt   648044
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37558 | Film No.: 181095941
SIC: 2834 Pharmaceutical Preparations